Amicus Therapeutics, Inc. (NASDAQ:FOLD Get Rating) has been assigned an average rating of Moderate Buy from the six brokerages that are currently covering the company, MarketBeat.com reports. Two research analysts have rated the stock with a hold rating and four have assigned a buy rating to the ...

European Commission Approval of Opfolda and Commercial Launch of Pombiliti + Opfolda Anticipated in 3Q 2023 Upon Approval, Pombiliti + Opfolda will be the First Two-Component Therapy in the European Union for the Treatment of Adults Living with Late-Onset Pompe Disease PHILADELPHIA, April 26, 2023 (...

Amicus Therapeutics, Inc. (NASDAQ:FOLD Get Rating) Chairman John F. Crowley sold 6,044 shares of the firms stock in a transaction that occurred on Monday, April 17th. The stock was sold at an average price of $11.66, for a total transaction of $70,473.04. Following the sale, the chairman now owns ...

PHILADELPHIA, Feb. 27, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in a fireside chat at the Cowen 43rd Annual Health Care Conference in Boston, MA on Monday, March 6, 2023 at 9:50 a.m. E.T. A live audio webcast of the presentation can...

CHMP Adopts Positive Opinion Based Upon Complete Review of all Pre-Clinical, Clinical Studies and CMC Data CHMP Recommends Label for Long-Term Enzyme Replacement Therapy in Combination with Miglustat for both ERT-Experienced and Treatment-Nave Adults Living with Late-Onset Pompe Disease CHMP Opinion...